… We summarize the preclinical and clinical trials, and provide … Therefore, targeting both
OXPHOS and glycolysis is … In summary, targeting immune checkpoints and VEGF/VEGFR is …

… inhibition of FGF2 and VEGF-A in preclinical models of head … treatment of sorafenib and
autophagy inhibitors[104], the dual … RAF), which has been established for metastatic colorectal …

… vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR)… , sorafenib (Nexavar), a
multikinase inhibitor targeting RAF … In summary, our preclinical studies indicated that targeting …

… by RAF mutations and in which selective RAF and MEK … of optimal combinations of sorafenib
(and anti-VEGF/R agents) … , and thus increase the relevance of the preclinical studies (12). …

… RAF, c-Kit, FLT-3 and RET are drug targets of sorafenib in tumor … Patients with elevated
serum VEGF benefit more from sorafenib … In summary, many preclinical and clinical trials have …

… VEGF/VEGFR axis displays an attractive target for anti-angiogenesis and anti-cancer drug
design. This review … these inhibitors on BC, we discuss sunitinib [SU11248], sorafenib [BAY 43…

… Regorafenib, a sorafenib derivative, targets kinases … Different strategies to inhibit vascular
endothelial growth factor (VEGF) or … tumor activity and targets the RAF/MEK/ERK pathway and …

… expanded with the introduction of novel chemotherapeutic … Sorafenib is a multi-kinase
inhibitor that targets several serine-… Although preclinical models suggested some anticancer …

… Within the MAPK pathway, the RAF proteins serve as master regulators of a myriad of … kinase
inhibitors, which may sensitize cancer to VEGF inhibitors [92]. As for the molecule sorafenib…

… RAF inhibitors with enhanced therapeutic profiles. Additionally, this review sheds light on
the functional interplay between RAF-… strategies using both RAF and MEK inhibitors may …